Applications of 2-Fluoro-DL-Phenylalanine in Industrial Manufacturing

2-Fluoro-DL-Phenylalanine serves as a fluorinated amino acid intermediate widely utilized in several specialized sectors, enabling the production of advanced pharmaceuticals, diagnostic reagents, and biochemical research tools. As a direct manufacturer, we supply this non-canonical amino acid meeting consistent, controlled quality specifications for demanding processes downstream. Below we outline precise downstream application scenarios, practical usage information, and compliance frameworks pertinent to industrial-scale implementation.

1. Active Pharmaceutical Ingredient (API) Synthesis: Anticancer Drug Intermediates

Pharmaceutical companies use 2-Fluoro-DL-Phenylalanine as a strategic building block during multi-step synthesis of fluorinated analogues of chemotherapeutic agents, particularly in pipelines targeting enzyme inhibition and metabolic pathway modulation. Manufacturers incorporate this raw material early in the process to introduce fluorine atoms that confer enhanced metabolic stability or altered receptor binding characteristics. Process engineers closely monitor addition timing and proportion to maximize yield and meet stringent regulatory filings.

Industry compliance standards

• International Council for Harmonisation (ICH Q7) for Good Manufacturing Practice (GMP) of APIs
• Relevant United States Pharmacopeia (USP) and European Pharmacopoeia (Ph. Eur.) monographs for amino acid intermediates
• FDA 21 CFR Part 211: Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs
• REACH registration for chemical intermediates in the EU

Typical usage ratio

• Typically 1–4 molar equivalents per synthetic reaction step, adjusted based on target molecule scale and reaction pathway optimization

Downstream process integration

• Incorporated during protected peptide chain assembly or direct fluorination steps, before deprotection and purification stages within the API synthesis route

Final product types

• Fluorinated peptide or small molecule oncology drugs (e.g., irreversible enzyme inhibitors containing fluoro-aromatic motifs)
• Patented investigational pharmaceuticals for metabolic disorders

2. Peptide Research and Proteomics: Incorporation in Fluorinated Peptides

Contract research organizations (CROs) and academic research centers value this material when synthesizing site-specifically fluorinated peptide libraries for structural biology and protein engineering. Direct incorporation enables NMR spectroscopy, PET imaging probe development, and detailed conformational analyses. The fluorinated residue often replaces natural phenylalanine or acts as a tag for advanced protein studies.

Industry compliance standards

• ISO 13485: Quality Management Systems for Medical Devices (applicable to reagents used in diagnostics research)
• OECD Principles of Good Laboratory Practice (GLP) for safety and traceability
• Relevant institutional review board (IRB) policies if used for preclinical research in regulated settings

Typical usage ratio

• Commonly 1–2 residue substitutions per peptide sequence, or up to 10% of total amino acid pool in combinatorial library synthesis

Downstream process integration

• Loaded onto automated peptide synthesizers at designated coupling cycle(s), followed by standard cleavage, deprotection, and purification protocols

Final product types

• Site-specifically labeled fluorinated peptides for NMR and X-ray crystallography
• Model substrates for enzyme assay development
• Proteomic probes and imaging agents containing aromatic fluoro-tagging

3. Radiopharmaceutical Precursor Manufacturing

Specialty radiochemistry labs utilize the compound as a molecular precursor for synthesis of positron emission tomography (PET) tracers, notably for labeling with fluorine-18. Its chemical structure supports late-stage radiofluorination, leading to tracers that target amino acid transporters or visualize specific metabolic pathways in vivo.

Industry compliance standards

• Good Manufacturing Practice (GMP) for investigational radiopharmaceuticals as per EMA and FDA guidance
• Pharmacopoeia Monographs (USP Chapter <823>, Ph. Eur. 5.19 on radiopharmaceutical preparations)
• Radiation safety regulations (IAEA Safety Standards, local radioprotection legislations)

Typical usage ratio

• Used at 0.2–1.0 mmol starting material per batch in automated or semi-automated radiosynthesis depending on cyclotron output and tracer demand

Downstream process integration

• Fed into nucleophilic substitution reactions with [18F]-fluoride, followed by rapid chromatographic purification prior to formulation and sterilization for human injection studies

Final product types

• 18F-labeled amino acid PET tracers for tumor imaging
• Preclinical radiotracer standards for translational research

4. Enzyme Inhibitor Design and Pharmaceutical Screening

Medicinal chemistry teams employ 2-Fluoro-DL-Phenylalanine in early-phase lead optimization to generate fluorinated analogues of peptide-based enzyme inhibitors. Introducing a fluoro-substituent at the phenyl ring modulates electronic profiles, impacting activity and selectivity screens. This approach supports structure–activity relationship (SAR) studies and generation of proprietary compound libraries for high-throughput biological evaluation.

Industry compliance standards

• ISO 9001 for quality management in discovery chemistry
• Guidance for Industry: Nonclinical Safety Evaluation of Reformulated Drug Products and Products Intended for Administration by an Alternate Route
• Good Laboratory Practice (GLP) regulations outlined by the FDA and OECD

Typical usage ratio

• Ranging from 1–3 mol% substitution within target peptide or small molecule scaffolds, depending on the size and biological target profile

Downstream process integration

• Integrated during solid-phase synthesis (SPS) or solution-phase organic synthesis, with purification by HPLC before bioassay screening

Final product types

• Patent-protected peptide-based enzyme inhibitors for drug discovery
• Biochemical reference standards for pharmaceutical development